サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1668474

臓器移植用免疫抑制剤の世界市場レポート 2025年

Organ Transplant Immunosuppressant Drugs Global Market Report 2025

出版日
ページ情報
英文 200 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
臓器移植用免疫抑制剤の世界市場レポート 2025年
出版日: 2025年02月28日
発行: The Business Research Company
ページ情報: 英文 200 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

臓器移植用免疫抑制剤の市場規模は、今後数年間で安定した成長が見込まれます。2029年にはCAGR4.6％で66億1,000万米ドルに成長します。予測期間の成長は、新たな治療法、臓器不全の発生率の上昇、個別化医療、世界ヘルスへの取り組み、国際的な連携に起因すると考えられます。予測期間における主な動向としては、技術革新、技術の進歩、コスト抑制戦略、市場統合と提携、臓器移植の増加などが挙げられます。

臓器移植に対する需要の高まりは、臓器移植用免疫抑制剤市場を強化すると予想されます。臓器移植は、人の体内の病気や損傷を受けた臓器を、ドナーの健康な臓器と外科的に置き換えることを含みます。この救命処置は、機能不全に陥った臓器を置き換えるために極めて重要であり、免疫抑制剤は、臓器不全の原因となる移植臓器の拒絶反応を防ぐ上で重要な役割を果たしています。これらの薬剤の入手可能性と有効性は、移植の成功に不可欠です。例えば、米国を拠点とする官民パートナーシップである臓器調達・移植ネットワーク（OPTN）は、2023年、約16,335人が逝去後に1つ以上の臓器を提供したと報告しました。これは、死亡ドナーが15,000人を超えた最初の年となり、2022年からの9.6％増を反映しています。このように、臓器移植に対する需要の高まりが臓器移植用免疫抑制剤市場の成長を牽引しています。

老年人口の拡大は、臓器移植用免疫抑制剤市場の成長を促進すると予測されています。免疫抑制剤は高齢の移植レシピエントにとって極めて重要であり、潜在的な副作用や薬物相互作用を軽減しながら拒絶反応を防ぐために、オーダーメイドの薬物レジメンが必要となります。世界保健機関（WHO）は、2030年までに世界の6人に1人が60歳以上の高齢者になり、その数は14億人に達し、2050年までに21億人に倍増すると予測しています。この人口動態の変化は、老年人口の拡大による市場の成長を裏付けています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

  • 世界臓器移植用免疫抑制剤PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
  • 最終用途産業の分析
  • 世界の臓器移植用免疫抑制剤市場：成長率分析
  • 世界の臓器移植用免疫抑制剤市場の実績：規模と成長, 2019-2024
  • 世界の臓器移植用免疫抑制剤市場の予測：規模と成長, 2024-2029, 2034F
  • 世界臓器移植用免疫抑制剤総アドレス可能市場（TAM）

第6章 市場セグメンテーション

  • 世界の臓器移植用免疫抑制剤市場薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • カルシニューリン阻害剤
  • 抗増殖剤
  • mTOR阻害剤
  • ステロイド
  • その他の薬物クラス
  • 世界の臓器移植用免疫抑制剤市場移植の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 心臓
  • 腎臓
  • 肝臓
  • 肺
  • 膵臓
  • その他の移植の種類
  • 世界の臓器移植用免疫抑制剤市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 病院薬局
  • 小売薬局
  • オンライン薬局
  • 世界の臓器移植用免疫抑制剤市場カルシニューリン阻害剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
  • シクロスポリン
  • タクロリムス
  • 世界の臓器移植用免疫抑制剤市場、抗増殖剤の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
  • アザチオプリン
  • ミコフェノール酸モフェチル
  • ミコフェノール酸
  • 世界の臓器移植用免疫抑制剤市場mTOR阻害剤の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
  • シロリムス
  • エベロリムス
  • 世界の臓器移植用免疫抑制剤市場ステロイドのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • プレドニゾン
  • メチルプレドニゾロン
  • 世界の臓器移植用免疫抑制剤市場、その他の薬物クラスのタイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 共刺激阻害薬
  • ナトリウムチャネル遮断薬
  • 抗体ベースの治療法

第7章 地域別・国別分析

  • 世界の臓器移植用免疫抑制剤市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 世界の臓器移植用免疫抑制剤市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 臓器移植用免疫抑制剤市場：競合情勢
  • 臓器移植用免疫抑制剤市場：企業プロファイル
    • Astellas Pharma Inc. Overview, Products and Services, Strategy and Financial Analysis
    • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
    • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
    • Accord Healthcare Limited Overview, Products and Services, Strategy and Financial Analysis
    • GlaxoSmithKline PLC Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

  • Pfizer Inc.
  • Sanofi S.A.
  • Alsachim a Shimadzu Group Company
  • Neovii Pharmaceuticals AG
  • Zydus Lifesciences Limited
  • Dr. Reddy's Laboratories Ltd.
  • Lupin Limited
  • Mylan N.V.
  • Strides Pharma Global Pte Ltd.
  • Asahi Kasei Corporation
  • Bristol-Myers Squibb Company
  • Veloxis Pharmaceuticals A/S
  • Viatris Inc.
  • Janssen Pharmaceuticals Inc.
  • AbbVie Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

  • 臓器移植用免疫抑制剤市場2029：新たな機会を提供する国
  • 臓器移植用免疫抑制剤市場2029：新たな機会を提供するセグメント
  • 臓器移植用免疫抑制剤市場2029：成長戦略
    • 市場動向に基づく戦略
    • 競合の戦略

第36章 付録

目次
Product Code: r24382

Organ transplant immunosuppressant drugs are crucial medications employed to curb the immune response in transplant recipients, mitigating the risk of rejection against the transplanted organ.

These drugs primarily fall into several classes calcineurin inhibitors, antiproliferative agents, mTOR inhibitors, steroids, and other miscellaneous classes. Calcineurin, an enzyme pivotal in T-cell activation, prompts the immune system to attack transplanted organs. Calcineurin inhibitors serve to prevent such rejection reactions in patients undergoing organ transplantation. These drugs find extensive use in heart, kidney, liver, lung, pancreas, and other organ transplants, and they are typically dispensed through hospital pharmacies, retail outlets, and online pharmacy platforms.

The organ transplant immunosuppressant drugs market research report is one of a series of new reports from The Business Research Company that provides organ transplant immunosuppressant drugs market statistics, including organ transplant immunosuppressant drugs industry global market size, regional shares, competitors with an organ transplant immunosuppressant drugs market share, detailed organ transplant immunosuppressant drugs market segments, market trends and opportunities, and any further data you may need to thrive in the organ transplant immunosuppressant drugs industry. This organ transplant immunosuppressant drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The organ transplant immunosuppressant drugs market size has grown steadily in recent years. It will grow from$5.35 billion in 2024 to $5.52 billion in 2025 at a compound annual growth rate (CAGR) of 3.2%. The growth in the historic period can be attributed to increased transplant procedures, improved healthcare infrastructure, research and development, a global aging population, and increasing awareness

The organ transplant immunosuppressant drugs market size is expected to see steady growth in the next few years. It will grow to $6.61 billion in 2029 at a compound annual growth rate (CAGR) of 4.6%. The growth in the forecast period can be attributed to emerging therapies, rising incidence of organ failures, personalized medicine, global health initiatives, and international collaboration. Major trends in the forecast period include technological innovations, technological advancements, cost containment strategies, market consolidation and partnerships, and increasing organ transplants.

The growing demand for organ transplantation is expected to enhance the organ transplant immunosuppressant drugs market. Organ transplantation involves surgically replacing a diseased or damaged organ in a person's body with a healthy organ from a donor. This life-saving procedure is crucial for replacing failed organs, and immunosuppressant drugs play a vital role in preventing the rejection of transplanted organs, which can result in organ failure. The availability and effectiveness of these drugs are critical to the success of transplantation. For example, in 2023, the Organ Procurement and Transplantation Network (OPTN), a U.S.-based public-private partnership, reported that approximately 16,335 individuals donated one or more organs after their passing. This marks the first year with over 15,000 deceased donors, reflecting a 9.6% increase from 2022. Thus, the rising demand for organ transplantation is driving growth in the organ transplant immunosuppressant drugs market.

The expanding geriatric population is projected to fuel the growth of the organ transplant immunosuppressant drugs market. Immunosuppressants are crucial for elderly transplant recipients, necessitating tailored drug regimens to prevent rejection while mitigating potential adverse effects and drug interactions. By 2030, the World Health Organization estimates that 1 in 6 people worldwide will be aged 60 or older, reaching 1.4 billion, doubling to 2.1 billion by 2050. This demographic shift underscores the market's growth driven by the expanding geriatric populace.

Product innovation is a significant trend in the organ transplant immunosuppressant drugs market. Major companies in this sector are concentrating on developing innovative solutions, such as combination therapies, to maintain their competitive edge. Combination therapy, which utilizes two or more immunosuppressant drugs, is becoming increasingly common as it can offer enhanced immunosuppression while minimizing the risk of side effects. For example, in March 2024, Johnson & Johnson, a U.S.-based pharmaceutical and biotechnology firm, received approval from the U.S. Food and Drug Administration (FDA) for OPSYNVI. This single-tablet combination is designed for the long-term management of pulmonary arterial hypertension (PAH) and includes tadalafil, a phosphodiesterase 5 (PDE5) inhibitor, and macitentan, an endothelin receptor antagonist (ERA). OPSYNVI can be prescribed to patients with PAH who are either new to treatment or currently using an ERA, PDE5 inhibitor, or both. Additionally, patients who are taking consistent doses of macitentan 10 mg and tadalafil 40 mg (20 mg x 2) as separate tablets may be switched to OPSYNVI.

Market leaders in the organ transplant immunosuppressant drugs sector prioritize advanced drug solutions to augment their product portfolios and meet patient needs. Advanced medications aim to modulate the immune system in transplant recipients. For instance, in August 2023, Strides Pharma Science Ltd. secured USFDA approval for Cyclosporine Softgel Capsules USP (Modified), catering to kidney, liver, and heart transplant recipients. This approval reinforces Strides' position in the immunosuppressant market, complementing their existing offerings and enhancing patient care outcomes.

In January 2022, CareDx, Inc., a U.S.-based precision medicine company, acquired The Transplant Pharmacy for an undisclosed amount. This acquisition allows CareDx, Inc. to enhance its medication management portfolio, particularly in the area of organ transplantation. The Transplant Pharmacy specializes in providing transplant services at various locations, delivering personalized patient care that includes online patient portal services and a mobile app for medication management.

Major companies operating in the organ transplant immunosuppressant drugs market include Astellas Pharma Inc., F. Hoffmann-La Roche AG, Novartis AG, Accord Healthcare Limited, GlaxoSmithKline PLC, Pfizer Inc., Sanofi S.A., Alsachim a Shimadzu Group Company, Neovii Pharmaceuticals AG, Zydus Lifesciences Limited, Dr. Reddy's Laboratories Ltd., Lupin Limited, Mylan N.V., Strides Pharma Global Pte Ltd., Asahi Kasei Corporation, Bristol-Myers Squibb Company, Veloxis Pharmaceuticals A/S, Viatris Inc., Janssen Pharmaceuticals Inc., AbbVie Inc., Hansa Biopharma AB, Wockhardt Ltd, Glenmark Pharmaceuticals Ltd., Biocon Ltd., Hikma Pharmaceuticals PLC, Teva Pharmaceutical Industries Ltd., Cipla Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Intas Pharmaceuticals Limited, Alkem Laboratories Limited, Torrent Pharmaceuticals Limited

North America was the largest region in the organ transplant immunosuppressant drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global organ transplant immunosuppressant drugs market report during the forecast period. The regions covered in the organ transplant immunosuppressant drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the organ transplant immunosuppressant drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The organ transplant immunosuppressant drugs market consists of sales of drugs such asteroid-sparing immunosuppressants, prednisone, antineoplastics, monoclonal antibody drug, and immunosuppressive agents. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Organ Transplant Immunosuppressant Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on organ transplant immunosuppressant drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for organ transplant immunosuppressant drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The organ transplant immunosuppressant drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Drug Class: Calcineurin Inhibitors; Antiproliferative Agents; mTOR Inhibitor; Steroids; Others Drug Classes
  • 2) By Transplant Type: Heart; Kidney; Liver; Lung; Pancreas; Other Transplant Types
  • 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
  • Subsegments:
  • 1) By Calcineurin Inhibitors: Cyclosporine; Tacrolimus
  • 2) By Antiproliferative Agents: Azathioprine; Mycophenolate Mofetil; Mycophenolic Acid
  • 3) By MTOR Inhibitor: Sirolimus; Everolimus
  • 4) By Steroids: Prednisone; Methylprednisolone
  • 5) By Other Drug Classes: Costimulation Blockers; Sodium Channel Blockers; Antibody-Based Therapies
  • Companies Mentioned: Astellas Pharma Inc.; F. Hoffmann-La Roche AG; Novartis AG; Accord Healthcare Limited; GlaxoSmithKline PLC
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Organ Transplant Immunosuppressant Drugs Market Characteristics

3. Organ Transplant Immunosuppressant Drugs Market Trends And Strategies

4. Organ Transplant Immunosuppressant Drugs Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Organ Transplant Immunosuppressant Drugs Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Organ Transplant Immunosuppressant Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Organ Transplant Immunosuppressant Drugs Market Growth Rate Analysis
  • 5.4. Global Organ Transplant Immunosuppressant Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Organ Transplant Immunosuppressant Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Organ Transplant Immunosuppressant Drugs Total Addressable Market (TAM)

6. Organ Transplant Immunosuppressant Drugs Market Segmentation

  • 6.1. Global Organ Transplant Immunosuppressant Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Calcineurin Inhibitors
  • Antiproliferative Agents
  • mTOR Inhibitor
  • Steroids
  • Others Drug Classes
  • 6.2. Global Organ Transplant Immunosuppressant Drugs Market, Segmentation By Transplant Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Heart
  • Kidney
  • Liver
  • Lung
  • Pancreas
  • Other Transplant Types
  • 6.3. Global Organ Transplant Immunosuppressant Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • 6.4. Global Organ Transplant Immunosuppressant Drugs Market, Sub-Segmentation Of Calcineurin Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Cyclosporine
  • Tacrolimus
  • 6.5. Global Organ Transplant Immunosuppressant Drugs Market, Sub-Segmentation Of Antiproliferative Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Azathioprine
  • Mycophenolate Mofetil
  • Mycophenolic Acid
  • 6.6. Global Organ Transplant Immunosuppressant Drugs Market, Sub-Segmentation Of mTOR Inhibitor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Sirolimus
  • Everolimus
  • 6.7. Global Organ Transplant Immunosuppressant Drugs Market, Sub-Segmentation Of Steroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Prednisone
  • Methylprednisolone
  • 6.8. Global Organ Transplant Immunosuppressant Drugs Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Costimulation Blockers
  • Sodium Channel Blockers
  • Antibody-Based Therapies

7. Organ Transplant Immunosuppressant Drugs Market Regional And Country Analysis

  • 7.1. Global Organ Transplant Immunosuppressant Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Organ Transplant Immunosuppressant Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Organ Transplant Immunosuppressant Drugs Market

  • 8.1. Asia-Pacific Organ Transplant Immunosuppressant Drugs Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Organ Transplant Immunosuppressant Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Organ Transplant Immunosuppressant Drugs Market, Segmentation By Transplant Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Organ Transplant Immunosuppressant Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Organ Transplant Immunosuppressant Drugs Market

  • 9.1. China Organ Transplant Immunosuppressant Drugs Market Overview
  • 9.2. China Organ Transplant Immunosuppressant Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Organ Transplant Immunosuppressant Drugs Market, Segmentation By Transplant Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Organ Transplant Immunosuppressant Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Organ Transplant Immunosuppressant Drugs Market

  • 10.1. India Organ Transplant Immunosuppressant Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Organ Transplant Immunosuppressant Drugs Market, Segmentation By Transplant Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Organ Transplant Immunosuppressant Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Organ Transplant Immunosuppressant Drugs Market

  • 11.1. Japan Organ Transplant Immunosuppressant Drugs Market Overview
  • 11.2. Japan Organ Transplant Immunosuppressant Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Organ Transplant Immunosuppressant Drugs Market, Segmentation By Transplant Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Organ Transplant Immunosuppressant Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Organ Transplant Immunosuppressant Drugs Market

  • 12.1. Australia Organ Transplant Immunosuppressant Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Organ Transplant Immunosuppressant Drugs Market, Segmentation By Transplant Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Organ Transplant Immunosuppressant Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Organ Transplant Immunosuppressant Drugs Market

  • 13.1. Indonesia Organ Transplant Immunosuppressant Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Organ Transplant Immunosuppressant Drugs Market, Segmentation By Transplant Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Organ Transplant Immunosuppressant Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Organ Transplant Immunosuppressant Drugs Market

  • 14.1. South Korea Organ Transplant Immunosuppressant Drugs Market Overview
  • 14.2. South Korea Organ Transplant Immunosuppressant Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Organ Transplant Immunosuppressant Drugs Market, Segmentation By Transplant Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Organ Transplant Immunosuppressant Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Organ Transplant Immunosuppressant Drugs Market

  • 15.1. Western Europe Organ Transplant Immunosuppressant Drugs Market Overview
  • 15.2. Western Europe Organ Transplant Immunosuppressant Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Organ Transplant Immunosuppressant Drugs Market, Segmentation By Transplant Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Organ Transplant Immunosuppressant Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Organ Transplant Immunosuppressant Drugs Market

  • 16.1. UK Organ Transplant Immunosuppressant Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Organ Transplant Immunosuppressant Drugs Market, Segmentation By Transplant Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Organ Transplant Immunosuppressant Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Organ Transplant Immunosuppressant Drugs Market

  • 17.1. Germany Organ Transplant Immunosuppressant Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Organ Transplant Immunosuppressant Drugs Market, Segmentation By Transplant Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Organ Transplant Immunosuppressant Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Organ Transplant Immunosuppressant Drugs Market

  • 18.1. France Organ Transplant Immunosuppressant Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Organ Transplant Immunosuppressant Drugs Market, Segmentation By Transplant Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Organ Transplant Immunosuppressant Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Organ Transplant Immunosuppressant Drugs Market

  • 19.1. Italy Organ Transplant Immunosuppressant Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Organ Transplant Immunosuppressant Drugs Market, Segmentation By Transplant Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Organ Transplant Immunosuppressant Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Organ Transplant Immunosuppressant Drugs Market

  • 20.1. Spain Organ Transplant Immunosuppressant Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Organ Transplant Immunosuppressant Drugs Market, Segmentation By Transplant Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Organ Transplant Immunosuppressant Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Organ Transplant Immunosuppressant Drugs Market

  • 21.1. Eastern Europe Organ Transplant Immunosuppressant Drugs Market Overview
  • 21.2. Eastern Europe Organ Transplant Immunosuppressant Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Organ Transplant Immunosuppressant Drugs Market, Segmentation By Transplant Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Organ Transplant Immunosuppressant Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Organ Transplant Immunosuppressant Drugs Market

  • 22.1. Russia Organ Transplant Immunosuppressant Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Organ Transplant Immunosuppressant Drugs Market, Segmentation By Transplant Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Organ Transplant Immunosuppressant Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Organ Transplant Immunosuppressant Drugs Market

  • 23.1. North America Organ Transplant Immunosuppressant Drugs Market Overview
  • 23.2. North America Organ Transplant Immunosuppressant Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Organ Transplant Immunosuppressant Drugs Market, Segmentation By Transplant Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Organ Transplant Immunosuppressant Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Organ Transplant Immunosuppressant Drugs Market

  • 24.1. USA Organ Transplant Immunosuppressant Drugs Market Overview
  • 24.2. USA Organ Transplant Immunosuppressant Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Organ Transplant Immunosuppressant Drugs Market, Segmentation By Transplant Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Organ Transplant Immunosuppressant Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Organ Transplant Immunosuppressant Drugs Market

  • 25.1. Canada Organ Transplant Immunosuppressant Drugs Market Overview
  • 25.2. Canada Organ Transplant Immunosuppressant Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Organ Transplant Immunosuppressant Drugs Market, Segmentation By Transplant Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Organ Transplant Immunosuppressant Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Organ Transplant Immunosuppressant Drugs Market

  • 26.1. South America Organ Transplant Immunosuppressant Drugs Market Overview
  • 26.2. South America Organ Transplant Immunosuppressant Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Organ Transplant Immunosuppressant Drugs Market, Segmentation By Transplant Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Organ Transplant Immunosuppressant Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Organ Transplant Immunosuppressant Drugs Market

  • 27.1. Brazil Organ Transplant Immunosuppressant Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Organ Transplant Immunosuppressant Drugs Market, Segmentation By Transplant Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Organ Transplant Immunosuppressant Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Organ Transplant Immunosuppressant Drugs Market

  • 28.1. Middle East Organ Transplant Immunosuppressant Drugs Market Overview
  • 28.2. Middle East Organ Transplant Immunosuppressant Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Organ Transplant Immunosuppressant Drugs Market, Segmentation By Transplant Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Organ Transplant Immunosuppressant Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Organ Transplant Immunosuppressant Drugs Market

  • 29.1. Africa Organ Transplant Immunosuppressant Drugs Market Overview
  • 29.2. Africa Organ Transplant Immunosuppressant Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Organ Transplant Immunosuppressant Drugs Market, Segmentation By Transplant Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Organ Transplant Immunosuppressant Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Organ Transplant Immunosuppressant Drugs Market Competitive Landscape And Company Profiles

  • 30.1. Organ Transplant Immunosuppressant Drugs Market Competitive Landscape
  • 30.2. Organ Transplant Immunosuppressant Drugs Market Company Profiles
    • 30.2.1. Astellas Pharma Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Accord Healthcare Limited Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. GlaxoSmithKline PLC Overview, Products and Services, Strategy and Financial Analysis

31. Organ Transplant Immunosuppressant Drugs Market Other Major And Innovative Companies

  • 31.1. Pfizer Inc.
  • 31.2. Sanofi S.A.
  • 31.3. Alsachim a Shimadzu Group Company
  • 31.4. Neovii Pharmaceuticals AG
  • 31.5. Zydus Lifesciences Limited
  • 31.6. Dr. Reddy's Laboratories Ltd.
  • 31.7. Lupin Limited
  • 31.8. Mylan N.V.
  • 31.9. Strides Pharma Global Pte Ltd.
  • 31.10. Asahi Kasei Corporation
  • 31.11. Bristol-Myers Squibb Company
  • 31.12. Veloxis Pharmaceuticals A/S
  • 31.13. Viatris Inc.
  • 31.14. Janssen Pharmaceuticals Inc.
  • 31.15. AbbVie Inc.

32. Global Organ Transplant Immunosuppressant Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Organ Transplant Immunosuppressant Drugs Market

34. Recent Developments In The Organ Transplant Immunosuppressant Drugs Market

35. Organ Transplant Immunosuppressant Drugs Market High Potential Countries, Segments and Strategies

  • 35.1 Organ Transplant Immunosuppressant Drugs Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Organ Transplant Immunosuppressant Drugs Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Organ Transplant Immunosuppressant Drugs Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer